spacer
home > ict > spring 2020 > managing trial data collection for success
PUBLICATIONS
International Clinical Trials

Managing Trial Data Collection for Success



Data collection has always been central to clinical research, but the breadth of information available today is truly unprecedented. It is not just that we have more data, it’s also that the data we are collecting are more complex. Clinical trial protocols have dramatically expanded the quantity and type of data being studied. New technologies, applications, and devices provide new information that has to be managed seamlessly.

Data collection must also keep pace with the fast-evolving world of clinical trial design. An example is the hybrid trial, which integrates a traditional randomised controlled trial with pragmatic design aspects to collect real-world patient outcome data. The nuances and complexities in this type of trial demand new approaches to data collection. Similarly, virtual trials are becoming increasingly important in a world where patients often live two hours or more from a testing site, and fear of contagion or inability to travel may preclude face-to-face meetings. To anticipate change and optimise success, companies must adapt, innovating new and flexible data collection methods. We must ensure data certainty with systems that are relevant, reliable, and precise.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Ed Seguine, CEO at Clinical Ink, is passionate about creating solutions for problems caused by current clinical trial processes and technologies. With more than 20 years of experience as a clinical technology executive at Big Pharma and startup organisations, Ed, a thought leader on key initiatives including CDISC and eClinical Forum, often presents at industry events and publishes regularly on the benefits of next-generation eSource solutions. He earned a Master of Business Administration from Indiana University- Bloomington, US, and a Bachelor of Science in Finance from Brigham Young University, US. eseguine@clinicalink.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

San Francisco, Calif. – February 16, 2022 – Unlearn®, developer of the Twintelligent RCT™, today announced that the company has entered into a multi-year collaboration with Merck KGaA, Darmstadt, Germany to accelerate late-stage clinical trials with novel trial designs that include Digital Twins. Initially, the collaboration will focus on advancing the regulatory approval of candidates in Merck KGaA, Darmstadt, Germany’s immunology pipeline, with the potential to expand into other therapeutic areas.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement